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Editorial

Targeting the STAT5 pathway in Ph+ acute lymphoblastic
leukemia
Valentina Minieri, Marco De Dominici, Marja T. Nevalainen and Bruno Calabretta
Ph+ ALL accounts for up to 25-30% of adult
ALL, and its clinical outcome remains unfavorable in
approximately 50% of the patients despite the introduction
of more effective induction and consolidation therapies
consisting of BCR-ABL1 tyrosine kinase inhibitors
(TKI) in combination with cytotoxic agents followed
by hematopoietic stem cell transplantation (HSCT) [1].
Resistance to TKIs develops in most patients through the
outgrowth of leukemic subclones carrying mutations in
the BCR-ABL1 kinase domain that impede the binding
of these drugs to the ATP-binding pocket. Less frequently,
resistance develops in the absence of tyrosine kinase
domain mutations, implying that BCR-ABL1-independent
mechanisms may be crucial in such instances. In particular,
such mechanisms may involve microenvironmentregulated pathways that bypass BCR-ABL1-dependent
cell-autonomous growth-promoting signals. Hence,
a more effective therapy of Ph+ ALL, especially at the
TKI-resistant stage, is likely to depend on targeting
growth-promoting pathways that are simultaneously
activated via cell-autonomous and microenvironmentdependent mechanisms. One such pathway is STAT5 that
is constitutively active in Ph+ ALL cells through BCRABL1 and can be activated by JAK2 via stroma-derived
cytokines (Figure 1).

The role of STAT5 for maintenance of oncogenic
ABL1-driven ALL has been previously investigated
in STAT5-deficient transgenic mice [2, 3]. Although
disease outcomes were, in part, influenced by the genetic
background of recipient mice, such studies supported
the relevance of STAT5 in growth and progression of
BCR-ABL1-driven leukemias. However, there is little
information on the requirement of STAT5 and STAT5regulated pathways in patient-derived Ph+ ALL and
whether such pathways can be targeted therapeutically in
xenograft models of human Ph+ ALL.
In a recently published study [4], we used genetic
and pharmacological approaches to investigate the
consequences of inhibiting the activity of STAT5 and
STAT5-regulated pathways for ex vivo growth and
leukemogenesis of Ph+ cell lines and patient-derived
newly diagnosed and relapsed/TKI-resistant Ph+ ALL.
Compared to controls, Ph+ ALL cell lines and
primary Ph+ ALL cells lentivirally transduced with a
STAT5 shRNA or treated with IST5-002, a recently
developed small molecule STAT5 inhibitor [5], exhibited
reduced cell growth and enhanced apoptosis. IST5-002
has been shown to inhibit phosphorylation, dimerization,
nuclear translocation, DNA binding and transcriptional
activity of STAT5 [5]. In addition, doxycycline-induced
activation of a STAT5 shRNA or treatment with IST5-002
led to a markedly increased survival of immunodeficient
mice injected with Ph+ ALL cell lines or Ph+ ALL cells
derived from a patient with TKI-resistant disease.
Induction of apoptosis in STAT5-silenced Ph+
ALL cells was associated with downregulation of BCL2 and MCL-1 and upregulation of BIM expression. In
STAT5-silenced Ph+ BV173 cells, apoptosis was rescued
by BIM silencing or by ectopic BCL-2 expression while
restoration of MCL-1 levels had no effects on cell viability.
However, it is possible that other Ph+ ALL cell lines and,
more importantly, primary Ph+ ALL cells rely on MCL-1
expression for their survival.
Inhibition of cell growth induced by STAT5
silencing in Ph+ ALL cells was also associated with
decreased expression of c-MYC and the PIM-1 kinase.
Surprisingly, restoring PIM-1 expression in STAT5silenced Ph+ ALL cells did not rescue growth inhibition
induced by STAT5 silencing. This is most likely due
to the inability of PIM-1 to suppress the apoptosis of
STAT5-silenced Ph+ ALL cells which is associated with
upregulation of BIM levels. In contrast, pharmacological

Figure 1: STAT5 activation in Ph+ ALL and pathway
inhibitors. STAT5 is phosphorylated and activated in Ph+ ALL
cells by means of JAK-dependent microenvironmental cues,
including activation of the IL-7 receptor, and, most importantly,
by BCR-ABL1, directly or via JAK2. STAT5 activity can be
prevented by inhibiting its phosphorylation by BCR-ABL1, by
using direct STAT5 inhibitors such as IST5-002 or by acting on
its transcriptional targets such as PIM-1 and BCL-2 proteins.
www.oncotarget.com

36726

Oncotarget

inhibition of PIM kinase by treatment with the PIM1/2
kinase inhibitor, AZD1208, suppressed proliferation and
colony formation of Ph+ ALL cells, including primary
leukemia cells from newly diagnosed and relapsed
patients. AZD1208 suppression of cell viability was
associated with decreased phosphorylation of known PIM
kinase targets such as the eukaryotic elongation factor 4EBP1, pro-apoptotic protein BAD, and MYC itself.
Based on these findings, we reasoned that
simultaneous targeting of STAT5-induced anti-apoptotic
and growth-promoting pathways may mimic the effects of
STAT5 silencing inducing a more effective suppression of
Ph+ ALL cell growth ex vivo and in mice.
Indeed, combined treatment of Ph+ ALL cells with
the pan-BCL-2 antagonist Sabutoclax and the PIM kinase
inhibitor AZD1208 suppressed colony formation and
leukemogenesis in immunodeficient mice more effectively
than either treatment alone.
In summary, this work supports the essential role of
STAT5 and STAT5-regulated pathways for maintenance
of Ph+ ALL cell growth. Most of the studies were based
on genetic silencing of STAT5 or modulation of STAT5regulated pathways in leukemic cells to suppress BCRABL1-driven STAT5 activity. However, pharmacological
inhibition of STAT5 and STAT5-regulated pathways
was also achieved ex vivo in cytokine-supplemented
cell cultures that may also promote STAT5 activation
independently of BCR-ABL1. Given that inhibition of
STAT5 activity and suppression of Ph+ ALL cell growth
were also achieved in these conditions, STAT5 inhibitors
may also disrupt microenvironment-dependent activation
of STAT5 in leukemic cells, possibly bypassing cellautonomous mechanisms of resistance to TKIs.
Our study supports the importance of further
development of STAT5 inhibitors for a therapy for BCRABL1-driven malignancies, especially at the stage of
TKI-resistant disease. However, until effective STAT5
inhibitors are brought to the clinic, the simultaneous
targeting of STAT5-dependent growth-promoting and
anti-apoptotic pathway may represent an alternative, while
other strategies may be also be investigated in parallel.
For example, increased expression of BIM was
observed in STAT5-silenced Ph+ ALL cells and BIM
silencing alone was sufficient to suppress the apoptosis of
these cells. BIM-mimetics [6] or drugs that enhance BIM
activity by blocking its binding to MCL-1 antagonists [7]
may also provide an alternative approach for the treatment
of TKI-resistant Ph+ ALL.
STAT5 is frequently activated in a cytokineindependent manner in Ph-like ALL due to mutations/
translocations of genes such as JAK2, CRLF2, ABL1,
CSF1R, and PDGFRB [8, 9]. Therefore targeting STAT5
or its downstream effectors may be beneficial for this
subset of patients as well.
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